Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium

BACKGROUND: We assessed the real world costs and cost-effectiveness of the addition of trastuzumab in HER2 positive early breast cancer compared to chemotherapy alone in the Dutch daily practice as opposed to the results based on trial data and based on a subset of patients that were treated accordi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Seferina, Shanly C., Ramaekers, Bram L.T., de Boer, Maaike, Dercksen, M. Wouter, van den Berkmortel, Franchette, van Kampen, Roel J.W., van de Wouw, Agnès J., Voogd, Adri C., Tjan Heijnen, Vivianne C.G., Joore, Manuela A.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Clinical Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5668034/
https://ncbi.nlm.nih.gov/pubmed/29108301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16985
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados